US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-22 01:39:04 Source:worldViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Previous:JoJo Siwa goes wild: Karma singer accused of getting drunk at Disney World after turning 21
Next:Seven sneaky clauses in estate agent contracts that can cost you dear
You may also like
- Pregnancy app used by the NHS accused of 'imposing gender ideology'
- Week in Politics: Luxon stands out, benefit action under scrutiny and grief over Efeso Collins
- Police reach end of pay negotiations, new offer on table
- Hope new research will help get answers for those with rare disorders
- Judge blocks Biden administration from enforcing new gun sales background check rule in Texas
- School truancy will leave 80
- With House speaker at his side, Trump suggests Ukraine aid should be loan
- EDITORIAL: Diet behind the times in dealing with same
- Strictly star Nadiya Bychkova reveals she doesn't know if she's on the show's 2024 line